Results 101 to 110 of about 623,354 (235)

Targeting peroxynitrite production in a model of persistent temporomandibular disorder comorbid with migraine

British Journal of Pharmacology, EarlyView.
Background and Purpose The persistence of temporomandibular disorders (TMDs), particularly myogenous, in a person with migraine can lead to exacerbated clinical outcomes and limited response to treatment. The pro‐nociceptive reactive nitroxidative species, peroxynitrite, is involved in migraine mechanisms, but little is known of its role in this ...
Simon Akerman, Ana Belen Salinas‐Abarca, Wei Guo, Daniela Salvemini, Marcela Romero‐Reyes   +4 more
wiley   +1 more source

Therapeutic access points: The roles of circumventricular organs in drug delivery and metabolic regulation

British Journal of Pharmacology, EarlyView.
The current obesity drug landscape, dominated by GLP‐1 receptor agonists and emerging multi‐agonist therapies, has reinforced that long‐term weight loss is achieved in large part through central mechanisms that suppress appetite and reshape energy balance.
Ines Martinez‐Corral, Nicholas Monaco, Daniel I. Brierley, Monica Imbernon   +3 more
wiley   +1 more source

Phloroglucinol inhibits human ureteral contractions via activation of cAMP‐PKA pathway

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Phloroglucinol is used to treat renal colic, especially when non‐steroidal anti‐inflammatory drugs are contraindicated. This study aimed to clarify its mechanism by examining effects on human ureteral contractility and underlying signalling pathways. Experimental Approach Urinary levels of neurokinin A (NKA), substance P
Hanwen Liu, Ruize Xu, Zihan Guan, Lei Liu, Guangda Lv, Weibo Chen, Jiliang Wen, Jianing Liu, Jieke Yan, Fangxin Gong, Pan Xiao, Xiulin Zhang, Lei Zhang   +12 more
wiley   +1 more source

G-protein coupling and signalling of Y1-like neuropeptide Y receptors in SK-N-MC cells

, 1991
We have studied [125I]neuropeptide Y-binding sites and neuropeptide Y-mediated second messenger responses in human SK-N-MC neuroblastoma cells with special reference to the role of G-proteins.
Rascher, W., Michel, M. C., Feth, F.
core  

Effects of 6‐OHDA‐Mediated Chemical Denervation of Sympathetic Axons in Inguinal Subcutaneous White Adipose Tissue

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims White adipose tissue (WAT) innervation by sensory and sympathetic axons contributes to tissue functions, but the consequences of selectively disrupting sympathetic input to WAT remain incompletely defined. Materials and Methods We utilised 6‐hydroxydopamine (6‐OHDA) as a validated approach to achieve bilateral sympathetic denervation of ...
Gilian Gunsch, Gargi Mishra, Magdalena Blaszkiewicz, Erica de Sousa, Jake W. Willows, Katharine W. Alltop, Annemarie Towle, Shawn Collins, Andre Khalil, Isabel F. Snodgrass, Lara Agha, Kiran Prakash, Rashmika Maganuru, Sugasini Dhavamani, John W. Newman, Kristy L. Townsend   +15 more
wiley   +1 more source

Intravenous Oxytocin Does Not Affect Glucose‐Regulating Hormones or Markers of Bone Turnover During Graded Glucose Infusion in Healthy Men

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aim Oxytocin has been proposed to exert glucose‐stabilising effects via modulation of pancreatic hormone secretion and to play a role in bone homeostasis. However, human data under controlled conditions are limited. We investigated the effects of intravenously infused oxytocin during a graded glucose infusion on glucose‐regulating hormones and
Vivian Kliim‐Hansen, Ida M. Gether, Aliya M. Thomas, Anne‐Marie Ellegaard, Miriam G. Pedersen, Jens J. Holst, Bolette Hartmann, Filip K. Knop, Lærke S. Gasbjerg, Asger B. Lund   +9 more
wiley   +1 more source

Real‐world outcomes of zavegepant use in a tertiary care setting using the Migraine Treatment Optimization Questionnaire‐5

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objectives/Background The introduction of calcitonin gene‐related peptide antagonists has transformed migraine care. Zavegepant, a third‐generation intranasal gepant, offers a nonoral treatment option for acute migraine. Although clinical trials support its efficacy and safety, real‐world data are limited.
Eric Dunn, Bradley Ong, Harpreet Kaur, Roman Popov, Claire Sonneborn, Aarushi Suneja   +5 more
wiley   +1 more source

Biochemical profiling and symptomatology of androgen deficiency in males with cluster headache: A prospective case–control study

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objectives/Background Cluster headache (CH) has historically been considered a male‐dominated disorder, suggesting a role for androgens in its pathophysiology. We aimed to evaluate hormone profiles and symptoms of androgen deficiency in CH.
Willemijn C. Naber, Roemer B. Brandt, Mariël Leon Morales‐Grooters, Ronald van der Wal, Sjoerd A. A. van den Berg, Jelle J. Goeman, Antoinette Maassen van den Brink, Rolf Fronczek   +7 more
wiley   +1 more source

Targeted liquid chromatography–tandem mass spectrometry profiling of arginine and histidine derivatives in chronic migraine: Discriminatory performance and changes after onabotulinumtoxinA therapy

Headache: The Journal of Head and Face Pain, EarlyView.
Plain Language Summary People with chronic migraine may have changes in amino‐acid metabolism, but it remains unclear which metabolic pathways are associated with the disease and early response to onabotulinumtoxinA treatment. We measured plasma amino‐acid levels in patients with chronic migraine and healthy controls and assessed changes after 1 month ...
Seyma Dumur, Kadidiatou Diarra, Joudy Sewidan, Julie Jalila Kalmoni, Demet Aygun, Dildar Konukoglu, Hafize Uzun   +6 more
wiley   +1 more source

Novel targets in headache: A narrative review

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objectives/Background This narrative review summarizes novel applications for the use of calcitonin gene‐related peptide (CGRP)‐targeted therapies that go beyond migraine, the latest updates with respect to targeting pituitary adenylate cyclase‐activating peptide (PACAP) as therapeutic in migraine, as well as exploring other more recently ...
Adriana Della Pietra, Peter J. Goadsby, Carolina Oldoni, Stephen Silberstein, Fred Cohen, Simon Akerman   +5 more
wiley   +1 more source